Analytical Data
-
Gene name
IL4I1
- Application
-
Alternative Names
IL4I1；FIG1；L-amino-acid oxidase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96RQ9
-
Expression Region
30-513aa
-
AA Sequence
QDPFEKCMQDPDYEQLLKVVTWGLNRTLKPQRVIVVGAGVAGLVAAKVLSDAGHKVTILEADNRIGGRIFTYRDQNTGWIGELGAMRMPSSHRILHKLCQGLGLNLTKFTQYDKNTWTEVHEVKLRNYVVEKVPEKLGYALRPQEKGHSPEDIYQMALNQALKDLKALGCRKAMKKFERHTLLEYLLGEGNLSRPAVQLLGDVMSEDGFFYLSFAEALRAHSCLSDRLQYSRIVGGWDLLPRALLSSLSGLVLLNAPVVAMTQGPHDVHVQIETSPPARNLKVLKADVVLLTASGPAVKRITFSPPLPRHMQEALRRLHYVPATKVFLSFRRPFWREEHIEGGHSNTDRPSRMIFYPPPREGALLLASYTWSDAAAAFAGLSREEALRLALDDVAALHGPVVRQLWDGTGVVKRWAEDQHSQGGFVVQPPALWQTEKDDWTVPYGRIYFAGEHTAYPHGWVETAVKSALRAAIKINSRKGPASD
-
Molecular Weight
61.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL4I1, or Interleukin 4 Inducible Protein 1, is a protein that has garnered significant interest in immunology and cancer research due to its role in modulating the immune response. Initially identified as an interferon-gamma-inducible protein, IL4I1 is known for its ability to catabolize tryptophan through the kynurenine pathway, which can influence T cell activation and enhance immune tolerance. This enzymatic activity has implications in various diseases, including cancer, where tumors often exploit immune evasion strategies. Recent studies have demonstrated that IL4I1 expression can be upregulated in certain cancers, thereby contributing to the immunosuppressive tumor microenvironment. Given its dual role in both promoting immune tolerance and potentially aiding tumor progression, researchers are keen to explore the therapeutic potentials of targeting IL4I1. By generating recombinant IL4I1 protein, scientists aim to elucidate its precise functions, validate its role as a biomarker for cancer prognosis, and evaluate its potential as a target for immunotherapy. Understanding IL4I1's mechanism of action may lead to novel strategies to enhance anti-tumor immunity and improve therapeutic outcomes in cancer patients. Hence, the study of IL4I1 and its recombinant forms stands at the intersection of immunology and oncology, offering pathways for innovative approaches to treating malignancies through modulation of immune responses.
